Drug intelligence / Profile preview

SBC003

Development stage: Preclinical
Lead developer: SunRegen Healthcare
Modality: Small Molecules
Administration: Oral

Overview

SBC003 is a preclinical neuroprotective drug candidate developed by SunRegen Healthcare for the treatment of neurodegenerative diseases, with an initial focus on Retinitis Pigmentosa (RP). The compound is designed to prevent or slow the degeneration of neurons, specifically photoreceptor cells in the retina. SBC003 was the primary asset involved in a proposed 2024-2025 reverse takeover (RTO) transaction between SunRegen Healthcare and Verisante Technology, which aimed to transition SunRegen into a public entity to fund Phase I/II clinical trials. The transaction was ultimately terminated in March 2025.

Beyond the preview

Go deeper on SBC003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBC003.

Explore the full profile